Chemotherapy-induced ileus and gastrointestinal hemorrhage following therapy with BrECADD for Hodgkin lymphoma: A case report

Abstract

A 62-year-old male with newly diagnosed advanced-stage Hodgkin lymphoma (HL) developed life-threatening gastrointestinal (GI) complications during brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone chemotherapy. He presented with chemotherapy-induced enteritis and jejunal ileus, followed by severe GI bleeding requiring two consecutive laparotomies and segmental jejunal resections. Histology revealed ulcerative jejunitis without signs of lymphoma infiltration. His medical course was further complicated by acute renal failure requiring dialysis. Although the patient temporarily stabilized with intensive care management, he subsequently developed Candida sepsis. At the time of submission, his outcome remains uncertain. This case underscores a rare but serious occurrence of GI toxicity associated with intensive chemotherapy for HL.

Keywords

Ileus / Enteritis / Hemorrhage / BrECADD / Hodgkin lymphoma

References

[1] Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): A randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024; 404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1

[2] German Hodgkin Study Group. Therapy - GHSG. Available from: https://en.ghsg.org/treatment [Last accessed on 2025 Jun 08].

[3] Akbarali HI, Muchhala KH, Jessup DK, Cheatham S.Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022; 155:131-166. doi: 10.1016/bs.acr.2022.02.007

[4] Carraro F, Rivetti E, Romano E, Fagioli F. Two cases of paralitic ileus in onco-hematologic patients. Pediatr Rep. 2012; 4(1):e3. doi: 10.4081/pr.2012.e3

[5] Mourad AP, De Robles MS. Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction - a case report. Int J Surg Case Rep. 2021; 79:131-134. doi: 10.1016/j.ijscr.2020.12.096

[6] Jiao XD, Luo X, Qin WX, Yuan LY, Zang YS. Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report. Mol Clin Oncol. 2016; 4(5):824-826. doi: 10.3892/mco.2016.782

[7] Roy R, Sarkar S. Paralytic ileus - a rare but serious side-effect of oral capecitabine. Int J Anat Radiol Surg. 2022; 11(1):SC01-SC02. doi: 10.7860/IJARS/2022/56456.2843

[8] Kumar KS, Balaji P, Muppa L. Paralytic ileus as a rare complication of vincristine therapy: A case report. Ind J Pharm Pract. 2024; 14(4):396-399. doi: 10.5530/ijopp.17.4.65

[9] Balu A, Nagarajan T, Mudawi H. Chemotherapy induced small bowel obstruction in small cell lung cancer. Arab J Gastroenterol. 2021; 22(3):246-248. doi: 10.1016/j.ajg.2021.07.001

[10] European Medicines Agency. Adcetris: EPAR - Product Information. Amsterdam: EMA; 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf [Last accessed on 2025 Jun 08].

[11] Gao S, Zhang M, Wu K, et al. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: A systematic review and meta-analysis. Expert Opin Drug Saf. 2020; 19(5):617-623. doi: 10.1080/14740338.2020.1718103

[12] Shi Y, Yao K, Zhao J, Yue Y, Wu H. Gastrointestinal toxicity of antibody-drug conjugates: A pharmacovigilance study using the FAERS database. BMC Pharmacol Toxicol. 2025;26:50. doi: 10.1186/s40360-025-00877-4

[13] O’Brien JW, Rogers M, Gallagher M, Rockall T.Management of massive gastrointestinal haemorrhage. Surgery (Oxford). 2022; 40(9):582-592.

[14] Hall T, Temperley HC, Mac Curtain BM, et al. Transcatheter arterial embolisation (TAE) totreat acute upper gastrointestinal bleeding secondary to gastric cancer: A systematic review and meta-analysis. Surgeon. 2024; 22(6):e213-e220. doi: 10.1016/j.surge.2024.09.009

[15] Lee KJ, Kim HM, Jung JW, et al. Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer. Gut Liver. 2013; 7(1):106-111. doi: 10.5009/gnl.2013.7.1.106

[16] Ferdinandus J, Kaul H, Fosså A, et al. PET-guided brecadd in older patients with advanced-stage classic hodgkin lymphoma: Results of the phase 2 part of the GHSG HD21 trial. Blood. 2024;144Suppl 1:568-568.

[17] Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV hodgkin’s lymphoma. N Engl J Med. 2018; 378(4):331-344. doi: 10.1056/NEJMoa1708984

[18] Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic hodgkin’s lymphoma. N Engl J Med. 2024; 391(15):1379-1389. doi: 10.1056/NEJMoa2405888